vs

Side-by-side financial comparison of STEVEN MADDEN, LTD. (SHOO) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $749.8M, roughly 2.0× STEVEN MADDEN, LTD.). Steris runs the higher net margin — 12.9% vs 3.3%, a 9.6% gap on every dollar of revenue. On growth, STEVEN MADDEN, LTD. posted the faster year-over-year revenue change (29.5% vs 9.2%). Steris produced more free cash flow last quarter ($199.5M vs $80.8M). Over the past eight quarters, STEVEN MADDEN, LTD.'s revenue compounded faster (16.7% CAGR vs 15.8%).

Steven Madden, Ltd. is a publicly traded company that designs and markets shoes and fashion accessories. Based in Long Island City, New York, the company's brands include Dolce Vita, Betsey Johnson, Blondo, BB Dakota and Mad Love. Steve Madden is also a licensee of various brands, including Anne Klein and Superga.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

SHOO vs STE — Head-to-Head

Bigger by revenue
STE
STE
2.0× larger
STE
$1.5B
$749.8M
SHOO
Growing faster (revenue YoY)
SHOO
SHOO
+20.4% gap
SHOO
29.5%
9.2%
STE
Higher net margin
STE
STE
9.6% more per $
STE
12.9%
3.3%
SHOO
More free cash flow
STE
STE
$118.7M more FCF
STE
$199.5M
$80.8M
SHOO
Faster 2-yr revenue CAGR
SHOO
SHOO
Annualised
SHOO
16.7%
15.8%
STE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
SHOO
SHOO
STE
STE
Revenue
$749.8M
$1.5B
Net Profit
$24.7M
$192.9M
Gross Margin
42.6%
43.8%
Operating Margin
4.8%
18.3%
Net Margin
3.3%
12.9%
Revenue YoY
29.5%
9.2%
Net Profit YoY
-34.8%
11.2%
EPS (diluted)
$0.33
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SHOO
SHOO
STE
STE
Q4 25
$749.8M
$1.5B
Q3 25
$664.2M
$1.5B
Q2 25
$556.1M
$1.4B
Q1 25
$551.4M
$1.5B
Q4 24
$578.8M
$1.4B
Q3 24
$621.2M
$1.3B
Q2 24
$521.7M
$1.3B
Q1 24
$550.6M
$1.1B
Net Profit
SHOO
SHOO
STE
STE
Q4 25
$24.7M
$192.9M
Q3 25
$20.5M
$191.9M
Q2 25
$-38.7M
$177.4M
Q1 25
$41.3M
$145.7M
Q4 24
$37.8M
$173.5M
Q3 24
$55.3M
$150.0M
Q2 24
$36.9M
$145.4M
Q1 24
$44.6M
$-1.4M
Gross Margin
SHOO
SHOO
STE
STE
Q4 25
42.6%
43.8%
Q3 25
41.8%
44.2%
Q2 25
40.6%
45.1%
Q1 25
41.0%
43.3%
Q4 24
40.7%
44.5%
Q3 24
41.8%
43.6%
Q2 24
41.6%
44.7%
Q1 24
40.8%
40.2%
Operating Margin
SHOO
SHOO
STE
STE
Q4 25
4.8%
18.3%
Q3 25
4.7%
18.2%
Q2 25
-7.2%
17.7%
Q1 25
9.7%
14.6%
Q4 24
8.1%
17.9%
Q3 24
12.0%
16.5%
Q2 24
9.0%
14.5%
Q1 24
10.3%
22.0%
Net Margin
SHOO
SHOO
STE
STE
Q4 25
3.3%
12.9%
Q3 25
3.1%
13.1%
Q2 25
-7.0%
12.8%
Q1 25
7.5%
9.8%
Q4 24
6.5%
12.7%
Q3 24
8.9%
11.3%
Q2 24
7.1%
11.4%
Q1 24
8.1%
-0.1%
EPS (diluted)
SHOO
SHOO
STE
STE
Q4 25
$0.33
$1.96
Q3 25
$0.29
$1.94
Q2 25
$-0.56
$1.79
Q1 25
$0.57
$1.48
Q4 24
$0.49
$1.75
Q3 24
$0.77
$1.51
Q2 24
$0.49
$1.46
Q1 24
$0.60
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SHOO
SHOO
STE
STE
Cash + ST InvestmentsLiquidity on hand
$112.4M
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$866.4M
$7.2B
Total Assets
$1.9B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SHOO
SHOO
STE
STE
Q4 25
$112.4M
$423.7M
Q3 25
$140.0K
$319.2M
Q2 25
$111.9M
$279.7M
Q1 25
$147.2M
$171.7M
Q4 24
$203.4M
$155.2M
Q3 24
$11.1M
$172.2M
Q2 24
$192.2M
$198.3M
Q1 24
$143.1M
$207.0M
Total Debt
SHOO
SHOO
STE
STE
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
SHOO
SHOO
STE
STE
Q4 25
$866.4M
$7.2B
Q3 25
$850.8M
$7.0B
Q2 25
$833.2M
$7.0B
Q1 25
$875.3M
$6.6B
Q4 24
$847.7M
$6.4B
Q3 24
$833.9M
$6.6B
Q2 24
$808.3M
$6.4B
Q1 24
$825.2M
$6.3B
Total Assets
SHOO
SHOO
STE
STE
Q4 25
$1.9B
$10.6B
Q3 25
$2.0B
$10.4B
Q2 25
$1.9B
$10.4B
Q1 25
$1.4B
$10.1B
Q4 24
$1.4B
$10.0B
Q3 24
$1.5B
$10.2B
Q2 24
$1.4B
$10.1B
Q1 24
$1.3B
$11.1B
Debt / Equity
SHOO
SHOO
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SHOO
SHOO
STE
STE
Operating Cash FlowLast quarter
$91.1M
$298.2M
Free Cash FlowOCF − Capex
$80.8M
$199.5M
FCF MarginFCF / Revenue
10.8%
13.3%
Capex IntensityCapex / Revenue
1.4%
6.6%
Cash ConversionOCF / Net Profit
3.70×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$119.5M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SHOO
SHOO
STE
STE
Q4 25
$91.1M
$298.2M
Q3 25
$23.4M
$287.8M
Q2 25
$66.5M
$420.0M
Q1 25
$-18.8M
$260.8M
Q4 24
$103.9M
$332.8M
Q3 24
$444.0K
$250.7M
Q2 24
$109.5M
$303.7M
Q1 24
$-15.7M
$254.8M
Free Cash Flow
SHOO
SHOO
STE
STE
Q4 25
$80.8M
$199.5M
Q3 25
$8.6M
$201.3M
Q2 25
$58.8M
$326.4M
Q1 25
$-28.7M
$189.9M
Q4 24
$94.6M
$243.6M
Q3 24
$-6.9M
$148.8M
Q2 24
$104.2M
$195.7M
Q1 24
$-19.7M
$163.3M
FCF Margin
SHOO
SHOO
STE
STE
Q4 25
10.8%
13.3%
Q3 25
1.3%
13.8%
Q2 25
10.6%
23.5%
Q1 25
-5.2%
12.8%
Q4 24
16.3%
17.8%
Q3 24
-1.1%
11.2%
Q2 24
20.0%
15.3%
Q1 24
-3.6%
14.6%
Capex Intensity
SHOO
SHOO
STE
STE
Q4 25
1.4%
6.6%
Q3 25
2.2%
5.9%
Q2 25
1.4%
6.7%
Q1 25
1.8%
4.8%
Q4 24
1.6%
6.5%
Q3 24
1.2%
7.7%
Q2 24
1.0%
8.4%
Q1 24
0.7%
8.2%
Cash Conversion
SHOO
SHOO
STE
STE
Q4 25
3.70×
1.55×
Q3 25
1.14×
1.50×
Q2 25
2.37×
Q1 25
-0.46×
1.79×
Q4 24
2.75×
1.92×
Q3 24
0.01×
1.67×
Q2 24
2.96×
2.09×
Q1 24
-0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SHOO
SHOO

Segment breakdown not available.

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons